hiv-1

HIV-1 Rev (34-50) (HIV-1 rev Protein (34-50)) is a 17-amino acid peptide with anti-HIV-1 activity, derived from the Rev-responsive element-binding domains of Rev in HIV-1.

(Cys47)-HIV-1 tat Protein (47-57) possesses membrane translocation functionality and can serve as a surface derivatization agent for magnetic pharmaceuticals, enhancing their uptake into specific target cells.

HIV-1, HIV-2 Protease Substrate serves as a substrate for the proteases of both HIV-1 and HIV-2, featuring four residues that permit conservative substitutions at the enzyme substrate binding sites [1].

Pol (476-484), HIV-1 RT Epitope, is a biologically active peptide representing the dominant HLA A*0201-restricted epitope within HIV-1 reverse transcriptase (RT). Spanning Pol residues 476-484, it is utilized to explore mechanisms of HIV-1 escape from cytotoxic T lymphocytes (CTL) with IV9 as the specific epitope processed and presented in HIV-1-infected cell lines.

HIV Protease Substrate 1 TFA, a fluorogenic substrate for HIV protease, facilitates the investigation of the enzyme's activity [1].

GP120, HIV-1 MN, a peptide, is utilized in researching HIV infection [1] [2].

HIV Protease Substrate 1 is a fluorogenic compound that offers insights into the enzymatic activity of HIV protease, making it a valuable tool for studying this aspect.

HIV-1 TAT (48-60) is a cell-penetrating peptide derived from the human immunodeficient virus (HIV)-1 Tat protein residue 48-60. This is one of the cell-penetrating peptides generated from the human immunodeficient virus -1 Tat protein residue 48-60.

HIV-1 TAT (48-60), a cell-penetrating peptide originating from residues 48-60 of the human immunodeficiency virus (HIV)-1 Tat protein, facilitates the non-disruptive delivery of exogenous macromolecules into cells.

Tat-beclin 1 acetate is a potent inducer of autophagy and interacts with the negative regulator of autophagy, GAPR-1. Tat-beclin 1 acetate decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens (including HIV-1).

Peptide T acetate is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a synthetic octapeptide whose possible mechanism of action is the competitive inhibition of gp120 to the CD4 receptor as well as binding to vasointestinal peptide receptors and inhibiting cytokine action

Cys-TAT(47-57) acetate is derived from the HIV-1 transactivating protein. Cys-TAT(47-57) acetate is an arginine rich peptide that can penetrate cells.

ALX 40-4C acetate is a CXCR4 inhibitor of the chemokine receptor (Ki = 1 μM) and suppresses the replication of X4 strains of HIV-1. ALX 40-4C acetate is an antagonist of the APJ receptor (IC50 = 2.9 μM).

TAT peptide (YGRKKRRQRRR), originating from the human immunodeficiency virus-1 (HIV-1) transactivator of transcription (TAT), enhances the solubility and production of heterologous proteins[1]. This cell-penetrating peptide demonstrates significant potential in biotechnological applications.

FC131 TFA (606968-52-9 free base) (FC131 TFA) is an antagonist of CXCR4 that inhibits the binding of [125I] -sdf-1 to CXCR4(IC50 : 4.5 nM ), and has anti-hiv activity.

HEP-1 (Human ezrin peptide (324-337)) is an orally active peptide with anti-HIV properties, shown to enhance antibody titers after hepatitis B vaccination. Its potential in viral infection treatment warrants further investigation [1].

SKF-107457 is an HIV protease type 1 inhibitor. It is a hexapeptide substrate analog with the scissile bond being replaced by a hydroxy ethylene isostere.

Cys-TAT(47-57) (Cys-[HIV-Tat (47-57)]) is an arginine-rich cell-penetrating peptide derived from the HIV-1 transactivating protein, corresponding to the protein transduction domain of the TAT protein.

H-Gly-Pro-Gly-NH2, a tripeptide, effectively inhibits HIV-1 replication by interfering with capsid formation, demonstrating antiviral activity particularly against HIV-1 III B and HIV-2 ROD with EC 50 values of 35 µM and 30 µM, respectively. This compound's ability to disrupt the viral replication process positions it as a valuable asset for virus research [1] [2] [3].

GluR23Y, a biologically active peptide, was utilized in an ELISA-based cell-surface assay to assess insulin-stimulated endocytosis of native AMPA receptors in cultured hippocampal neurons. GluR23Y effectively inhibited the insulin-induced decrease in receptor presence. The inhibition of insulin effects was achieved by introducing GluR23Y into neurons through fusion with the membrane transduction domain of HIV-1 TAT.

Retrocyclin-3 is an antimicrobial peptide exhibiting activity against human immunodeficiency virus (HIV), influenza A, and herpes simplex virus (HSV) [1].

Tat-Gap 19, a peptide inhibitor of connexin43 (Cx43) hemichannels, is derived from the HIV-1 Tat protein transduction domain fused with a nine-amino acid sequence from Cx43 residues 128-136. This compound, at a concentration of 10 µM, effectively suppresses glutamate-induced ATP release in primary rat hepatocytes, indicating inhibition of Cx43 hemichannel activity. Furthermore, Tat-Gap 19 demonstrates therapeutic potential by significantly reducing infarct volume in a mouse cerebral ischemia-reperfusion injury model following middle cerebral artery occlusion (MCAO) at a dosage of 25 mg/kg. Moreover, its intraperitoneal administration at 1 mg/kg per day ameliorates fibrosis and decreases the area of hepatic stellate cells, the precursors to myofibroblasts, expressing α-smooth muscle actin (α-SMA), in a model of thioacetamide-induced liver damage. Additionally, it enhances superoxide dismutase (SOD) activity in hepatic cells from the treated mice, indicating its antioxidative benefits.

F9170, an antiviral peptide derived from the HIV-1 envelope glycoprotein (amino acids 789-803), targets the LLP1 domain in the virus's envelope protein cytoplasmic tail. This interaction inhibits HIV-1 IIIB infection in MT-2 cells, evidenced by an EC50 value of 0.19 µM. Additionally, at a dosage of 3 mg/kg, F9170 significantly lowers plasma viral load in rhesus macaques infected with simian HIV (SHIV).

Cell-permeable calmodulin (CaM) agonist that binds to the EF-hand/Ca2+-binding site; produces CaM-dependent activation of phosphodiesterase. Also binds to cytoplasmic sites on other Ca2+ channels, including NMDA and HIV-1 gp120-activated channels, inhibit

Tat-beclin 1 TFA, a peptide derived from a segment of the autophagy protein beclin 1, effectively induces autophagy and interacts with the autophagy negative regulator GAPR-1 (GLIPR2). It reduces the accumulation of polyglutamine expansion protein aggregates and limits the in vitro replication of various pathogens, including HIV-1. Additionally, Tat-beclin 1 TFA has been shown to decrease mortality rates in mice infected with chikungunya (CHIKV) or West Nile virus (WNV) [1].

TC14012 TFA, a serum-stable derivative of T140, is a selective peptidomimetic CXCR4 antagonist with an IC50 value of 19.3 nM and also functions as a potent CXCR7 agonist, exhibiting an EC50 of 350 nM for recruiting β-arrestin 2 to CXCR7. This compound demonstrates anti-HIV and anti-cancer activities [1] [2].

ELDKWA, a highly conserved sequence of amino acids located on the ecto-domain of gp41, serves as the epitope for mAb 2F5, a neutralizing monoclonal antibody against human immunodeficiency virus type 1 [1] [2].

Polyphemusin II-Derived Peptide (T140), a CXCR4 inhibitor, effectively blocks HIV-1 entry and hinders the binding of the anti-CXCR4 monoclonal antibody (12G5) to CXCR4 [1].

α-Melanocyte-stimulating hormone (α-MSH) is a 13-amino acid peptide hormone produced by post-translational processing of proopiomelanocortin (POMC) in the pituitary gland, as well as in keratinocytes, astrocytes, monocytes, and gastrointestinal cells.1It is an agonist of melanocortin receptor 3 (MC3R) and MC4R that induces cAMP production in Hepa cells expressing the human receptors (EC50s = 0.16 and 56 nM, respectively).2α-MSH (100 pM) reducesS. aureuscolony formation andC. albicansgerm tube formationin vitro.3It inhibits endotoxin-, ceramide-, TNF-α-, or okadaic acid-induced activation of NF-κB in U937 cells.1α-MSH reduces IL-6- or TNF-α-induced ear edema in mice.4It also prevents the development of adjuvant-induced arthritis in rats and increases survival in a mouse model of septic shock. Increased plasma levels of α-MSH are positively correlated with delayed disease progression and reduced death in patients with HIV.1 1.Catania, A., Airaghi, L., Colombo, G., et al.α-melanocyte-stimulating hormone in normal human physiology and disease statesTrends Endocrinol. Metab.11(8)304-308(2000) 2.Miwa, H., Gantz, I., Konda, Y., et al.Structural determinants of the melanocortin peptides required for activation of melanocortin-3 and melanocortin-4 receptorsJ. Pharmacol. Exp. Ther.273(1)367-372(1995) 3.Cutuli, M., Cristiani, S., Lipton, J.M., et al.Antimicrobial effects of a-MSH peptidesJ. Leukoc. Biol.67(2)233-239(2000) 4.Lipton, J.M., Ceriani, G., Macaluso, A., et al.Antiiinflammatory effect of the neuropeptide a-MSH in acute, chronic, and systemic inflammationAnn. N.Y. Acad. Sci.25(741)137-148(1994)

Decanoyl-RVKR-CMK (DecRVKRcmk) TFA effectively hinders the processing of over-expressed gp160 and suppresses HIV-1 replication.

Defensin HNP-3 is a peptide secreted by human polymorphonuclear leukocytes (PMNs) that has antimicrobial properties. It induces lysis of mammalian cells when used at a concentration of 25 μg/mL. It also inhibits growth of E. faecalis (ED50 = 100 nM) and clinical isolates of P. aeruginosa (MIC90 = 4 μM). HNP-3 binds to recombinant HIV-1 envelope glycoprotein (gp120) and human CD4 (Kds = 52.8 and 34.9 nM, respectively). It also binds to recombinant, immobilized human surfactant protein D (SP-D; Kd = 55.7 nM) and inhibits focus formation in Madin-Darby canine kidney (MDCK) cells infected with influenza A virus (IAV).

Human α-defensin 5 is an antiviral peptide that inhibits the infection of non-enveloped viruses such as AdV, HPV, and polyomaviruses, with an IC50 range of 0.6-1.25 μM specifically for HPV16. It functions by binding to the viral capsid and preventing viral escape from the endosome. Additionally, Human α-defensin 5 enhances HIV attachment to the cell surface and exhibits parasiticidal activity [1].

Peptide T (TFA), an octapeptide derived from the V2 region of HIV-1 gp120, functions as a ligand for the CD4 receptor, thereby effectively inhibiting HIV binding to the CD4 receptor.

VIR-165 is a modified form of virus inhibitory peptide (VIRIP), corresponding to residues 353 to 372 of the C-proximal region of human alpha1-antitrypsin, the most abundant circulating serine protease inhibitor. VIRIP inhibits a wide variety of human immunodeficiency virus type 1 (HIV-1) strains.

Peptide T, an octapeptide from the V2 region of HIV-1 gp120, is a synthetic octapeptide that potentially acts through competitive inhibition of gp120 binding to the CD4 receptor, as well as binding to vasointestinal peptide receptors and inhibiting cytokine action.

HIV gag peptide (197-205) is an H-2Kd-restricted epitope derived from the p24 portion of the HIV-1 gag protein, composed of amino acids 197-205 (AMQMLKETI).

ALX40-4C is a small peptide inhibitor of the chemokine receptor CXCR4 that can inhibit X4 strains of HIV-1.

TAT-BH4 (Bcl-xL) TFA, primarily localized at the mitochondria, inhibits apoptotic cell death. This compound comprises an eosin-labeled cysteine at the N-terminal and the protein transduction domain from the HIV TAT protein (amino acids 49 to 57), fused to the Bcl-xL BH4 peptide. It is utilized in research concerning diseases associated with accelerated apoptosis [1].

Astodrimer (SPL7013 free base), a large (3-4 nm, ~16.5 kDa) and negatively charged dendrimer, possesses potent virucidal capabilities. Exhibiting antiviral and virucidal activities, it effectively targets a wide array of viruses, including SARS-CoV-2, HIV-1, HSV-1, HSV-2, and HPV. Additionally, Astodrimer demonstrates antibacterial properties [1] [2] [3].

GLR-19 is an anti-HIV peptide with demonstrated antiviral activity against HSV-2 [1] [2].

TRPV1-Tat, a peptide antagonist targeting transient receptor potential vanilloid 1 (TRPV1), is composed of amino acids 736-745 derived from TRPV1's A-kinase anchor protein (AKAP)-binding domain, combined with the HIV Tat-derived cell-penetrating peptide sequence. At a concentration of 200 µM, TRPV1-Tat effectively inhibits heat or phorbol 12-myristate 13-acetate (PMA014)-induced currents in primary mouse dorsal root ganglia via whole-cell patch-clamp assays. Additionally, when administered at dosages of 10 or 30 µM, it elevates the mechanical pain threshold in the hind paws of rats.

Enfuvirtide acetate salt is a linear synthetic peptide made of 36 amino acids. It has an acetylated N-terminus and a carboxamide C-terminus.

Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2 is a peptide substrate specific to HIV-1 protease, used as the variable component in peptidolytic assays designed to measure the enzyme's inhibition [1][2].

Tat-βsyn-degron, an α-synuclein knockdown peptide, integrates three domains: the HIV-1 Tat plasma membrane transduction domain, an α-synuclein binding domain (βsyn) representing amino acids 36-45 of β-synuclein, and a proteasomal targeting domain (degron). It effectively binds to recombinant α-synuclein, demonstrating a significant reduction in α-synuclein levels in primary rat cortical neuron cultures.

Tat-HA-NR2B9, comprising an HIV-1 Tat transduction domain fragment, an influenza virus hemagglutinin (HA) epitope-tag, and the C-terminal 9 amino acids of NR2B (NR2B9c), has demonstrated efficacy in reducing infarct size and enhancing neurological function following ischemia-induced cerebral injury in rats [1].

Apelin-36(rat, mouse) TFA, an endogenous agonist for the orphan G protein-coupled receptor APJ, exhibits a strong affinity for APJ receptors with an IC 50 of 5.4 nM and effectively inhibits cAMP production with an EC 50 of 0.52 nM. Moreover, it obstructs the invasion of certain HIV-1 and HIV-2 strains into NP-2/CD4 cells that express the APJ receptor [1] [2].

Apelin-17(human, bovine) TFA is an endogenous agonist of the orphan G protein-coupled receptor APJ, demonstrating affinity for human APJ receptors on HEK 293 cells with a pIC50 value of 9.02. It also blocks the entry of certain HIV-1 and HIV-2 strains into NP2 CD4 cells that express the APJ receptor [1] [2] [3].

Endogenous APJ receptor agonist (EC50 = 20 nM) that is secreted by adipocytes. Binds with high affinity to human APJ receptors expressed in HEK 293 cells (pIC50= 8.61). Involved in regulation of cardiovascular function, fluid homeostasis and feeding. Bloc